Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2012-12-27Clinical Trial Update: Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension [NA]
This entry describes genetic research investigating the bone morphogenetic protein receptor-II gene in a Taiwanese patient with primary pulm…
-
FDA approval · 2012-12-10FDA Approved: SILDENAFIL — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for sildenafil submitted by Chartwell RX, LLC under ANDA202598.
-
CLINICAL_TRIALS trial_result · 2012-11-09Clinical Trial Update: Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects [Phase 1]
Phase 1 trial assesses safety, tolerability, and pharmacokinetic parameters of inhaled sodium nitrite solution in healthy volunteers.
-
FDA approval · 2012-11-06FDA Approved: SILDENAFIL — Original Application (Chartwell RX, LLC)
FDA approved Chartwell RX, LLC's original ANDA for sildenafil, authorizing a generic version of sildenafil citrate.
-
CLINICAL_TRIALS trial_result · 2012-11-05Clinical Trial Update: Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)
Clinical trial SITAR evaluated switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. The study status is …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-10-31Clinical Trial Update: Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
A completed clinical trial evaluating the effectiveness, safety, and tolerability of sildenafil at doses ≥20 mg three times daily for pulmon…
-
CLINICAL_TRIALS trial_result · 2012-10-29Clinical Trial Update: Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension [Phase 3]
This clinical trial update reports the completion of a Phase 3 safety study extension for Iloprost Power 15 in pulmonary arterial hypertensi…
-
CLINICAL_TRIALS trial_result · 2012-10-26Clinical Trial Update: Iloprost Power 15 in Pulmonary Arterial Hypertension [Phase 3]
Phase 3 clinical trial of Iloprost Power 15 for pulmonary arterial hypertension has completed, with results posted in 2012.
-
FDA approval · 2012-10-19FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc.
-
FDA approval · 2012-10-04FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for Tracleer (bosentan) filed by Actelion Pharmaceuticals US, Inc. to update/expand the labeling for…
-
CLINICAL_TRIALS trial_result · 2012-10-04Clinical Trial Update: Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension [NA]
A Laval University–led clinical trial evaluating the responsiveness of exercise tests in pulmonary arterial hypertension has completed.
-
FDA approval · 2012-10-02FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for Tracleer (bosentan) from Actelion Pharmaceuticals US, Inc. The supplement updates the approved l…
-
FDA approval · 2012-08-30FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved a supplemental application for Revatio (sildenafil citrate) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2012-08-30FDA Approved: REVATIO — Original Application (Viatris Specialty LLC)
The FDA approved the original application for REVATIO (sildenafil citrate) filed by Viatris Specialty LLC. This approval supports the use of…
-
FDA approval · 2012-08-30FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2012-08-23Clinical Trial Update: Epoprostenol for Injection in Pulmonary Arterial Hypertension [Phase 4]
Phase 4 trial update for Epoprostenol for Injection in pulmonary arterial hypertension. The study has completed and results were posted in 2…
-
CLINICAL_TRIALS trial_result · 2012-08-23Clinical Trial Update: Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 [Phase 4]
Phase 4 extension study of Epoprostenol for Injection in pulmonary arterial hypertension with results posted.
-
CLINICAL_TRIALS trial_result · 2012-08-21Clinical Trial Update: Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH) [Phase 4]
This Phase 4 clinical trial evaluating the combination of bosentan and inhaled iloprost for idiopathic pulmonary arterial hypertension has b…
-
CLINICAL_TRIALS withdrawal · 2012-08-06Clinical Trial Update: Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH) [Phase 2]
A Phase 2 trial evaluating metformin as add-on therapy to standard treatment for pulmonary arterial hypertension (grade II/III) has been wit…
-
CLINICAL_TRIALS trial_result · 2012-07-30Clinical Trial Update: Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) [Phase 4]
Phase 4 ATHENA-1 evaluated adding ambrisentan to background PDE5 inhibitor therapy in pulmonary arterial hypertension; results were posted i…
-
CLINICAL_TRIALS other · 2012-07-25Clinical Trial Update: Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost [Phase 4]
This document reports a Phase 4 clinical trial evaluating vardenafil as an add-on therapy for patients with pulmonary arterial hypertension …
-
FDA approval · 2012-06-28FDA Approved: VELETRI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for VELETRI (epoprostenol) by Actelion Pharmaceuticals US, expanding its labeling.
-
CLINICAL_TRIALS research · 2012-06-25Clinical Trial Update: Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
A terminated clinical trial update about early, simple detection of pulmonary arterial hypertension in systemic sclerosis.
-
CLINICAL_TRIALS trial_result · 2012-06-20Clinical Trial Update: Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 study of ambrisentan for liver function test rescue in pulmonary arterial hypertension has completed, with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-06-08Clinical Trial Update: Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
Pilot chart review study of sitaxentan in patients with pulmonary arterial hypertension has completed with posted results.